<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Long-term antithrombotic therapy for the secondary prevention of ischemic stroke</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Long-term antithrombotic therapy for the secondary prevention of ischemic stroke</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Long-term antithrombotic therapy for the secondary prevention of ischemic stroke</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Brett L Cucchiara, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steven R Messé, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott E Kasner, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Dashe, MD, PhD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 08, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Antiplatelet therapy is used for both the management of acute ischemic stroke and for the prevention of stroke. Antiplatelet therapy reduces the incidence of stroke in patients at high risk for atherosclerosis and in those with known symptomatic cerebrovascular disease.</p><p>Antiplatelet therapy for secondary stroke prevention will be reviewed here. Antiplatelet therapy for acute ischemic stroke and for primary stroke prevention is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a> and  <a class="medical medical_review" href="/z/d/html/7573.html" rel="external">"Overview of primary prevention of cardiovascular disease"</a>.)</p><p>Prevention of recurrent stroke with antithrombotic therapy in patients with atrial fibrillation is reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p class="headingAnchor" id="H3636668982"><span class="h1">IMMEDIATE TREATMENT</span><span class="headingEndMark"> — </span>Short-term antithrombotic therapy after acute ischemic stroke or transient ischemic attack (TIA) may differ from long-term therapy. Antithrombotic treatment for patients in the first days to weeks after the onset of acute ischemic stroke or TIA, including the short-term use of dual antiplatelet therapy, is summarized in the algorithms  (<a class="graphic graphic_algorithm graphicRef131695" href="/z/d/graphic/131695.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131701" href="/z/d/graphic/131701.html" rel="external">algorithm 2</a>) and discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p>Importantly, despite evidence of benefit with short-term use in acute ischemic stroke, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> should not be used in combination for long-term stroke prevention, given the lack of greater efficacy compared with either agent alone, and given the substantially increased risk of bleeding complications. (See <a class="local">'Aspirin plus clopidogrel'</a> below.)</p><p class="headingAnchor" id="H4164479824"><span class="h1">LONG-TERM TREATMENT</span></p><p class="headingAnchor" id="H3930749768"><span class="h2">Choosing therapy</span><span class="headingEndMark"> — </span>For the long-term secondary prevention of stroke in patients with a history of noncardioembolic ischemic stroke or transient ischemic attack (TIA) of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type, we recommend treatment with an antiplatelet agent using either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, or <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>. (See <a class="local">'Aspirin'</a> below and <a class="local">'Clopidogrel'</a> below and <a class="local">'Aspirin plus dipyridamole'</a> below.)</p><p>The choice between <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, and <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> is dependent mainly on patient tolerance, contraindications, availability, and cost. All three are acceptable options for preventing recurrent noncardioembolic ischemic stroke [<a href="#rid1">1,2</a>]. We suggest antiplatelet therapy using either clopidogrel (75 mg daily) as monotherapy or the combination of aspirin-extended-release dipyridamole (25 mg/200 mg twice a day), rather than aspirin alone [<a href="#rid1">1</a>]. Compared with aspirin for the long-term secondary prevention of serious vascular events (ie, nonfatal stroke, nonfatal myocardial infarction, or vascular death), the benefit appears to be modestly greater with clopidogrel alone and with aspirin-extended-release dipyridamole [<a href="#rid3">3</a>]. (See <a class="local">'Clopidogrel'</a> below and <a class="local">'Aspirin plus dipyridamole'</a> below.)</p><p>Nevertheless, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is often used as the first-line agent [<a href="#rid4">4</a>], given that the apparent modest advantage in benefit of alternative antiplatelet regimens (<a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> or <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>) is potentially offset by a disadvantage in cost and access, since aspirin is available without a prescription. In addition, headache and gastrointestinal symptoms have limited the use of aspirin-extended-release dipyridamole [<a href="#rid4">4</a>]. Aspirin use is also associated with a decreased risk of colorectal cancer. (See  <a class="medical medical_review" href="/z/d/html/2600.html" rel="external">"NSAIDs (including aspirin): Role in prevention of colorectal cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16291.html" rel="external">"Aspirin in the primary prevention of cardiovascular disease and cancer"</a>.)</p><p>Other antiplatelet agents have a more limited role. <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> is a reasonable option for patients of East Asian ethnicity or for patients with allergies that preclude use of the other recommended antiplatelet medications, but there are no high-quality data regarding the use of cilostazol for secondary stroke prevention in non-East Asian ethnic groups. Also, the twice daily dosing, lower tolerability, and higher cost of cilostazol compared with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may limit its more widespread use for stroke prevention. (See <a class="local">'Cilostazol'</a> below.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> combined with low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (2.5 orally twice a day) is another reasonable treatment option for some patients with non-lacunar, non-cardioembolic ischemic stroke and evidence of systemic atherosclerosis. (See <a class="local">'Combination antiplatelet and anticoagulant therapy'</a> below.)</p><p class="headingAnchor" id="H3417272397"><span class="h2">Specific clinical situations</span></p><p class="headingAnchor" id="H1474024836"><span class="h3">Antiplatelet intolerance or allergy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> is an appropriate option for patients unable to tolerate <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (including the combination drug <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>) due to allergy or gastrointestinal upset. <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> is a reasonable option if the other agents are not available or tolerated. <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">Ticagrelor</a> is another option for the small subset of patients who cannot take another first-line agent; examples include a patient allergic to aspirin who is also intolerant of clopidogrel or has a clopidogrel CYP2C19 poor metabolizer genotype. (See <a class="local">'Clopidogrel resistance'</a> below.)</p><p class="headingAnchor" id="H2051959832"><span class="h3">Patients having carotid revascularization</span><span class="headingEndMark"> — </span>Most patients having carotid endarterectomy are treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (81 to 325 mg daily) monotherapy started before surgery and continued indefinitely, barring a long-term indication for anticoagulation such as concomitant atrial fibrillation, while most patients having carotid stenting are treated with aspirin plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> for 30 days, followed by long-term single-agent antiplatelet therapy  (<a class="graphic graphic_algorithm graphicRef131695" href="/z/d/graphic/131695.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131701" href="/z/d/graphic/131701.html" rel="external">algorithm 2</a>). The use of antiplatelet therapy for patients undergoing carotid endarterectomy or carotid stenting is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/8193.html" rel="external">"Carotid endarterectomy", section on 'Antiplatelet therapy'</a> and  <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">"Overview of carotid artery stenting", section on 'Dual antiplatelet therapy'</a>.)</p><p class="headingAnchor" id="H3538908067"><span class="h3">Patients of East Asian ethnicity</span><span class="headingEndMark"> — </span>Randomized controlled trial data support the safety and efficacy of <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> for secondary stroke prevention in East Asian populations. Therefore, cilostazol is a reasonable antiplatelet treatment option for patients of East Asian ethnicity. Efficacy may be similar in non-East Asian populations, but data are extremely limited. (See <a class="local">'Cilostazol'</a> below.)</p><p class="headingAnchor" id="H2256168133"><span class="h3">Patients with an indication for anticoagulation</span><span class="headingEndMark"> — </span>In general, patients with a history of ischemic stroke or TIA due to atrial fibrillation or another condition that requires anticoagulation are not treated with antiplatelet therapy due to the increased risk of bleeding.</p><p>Note that a history of cryptogenic stroke, including embolic stroke of undetermined source (ESUS), is generally not an indication for anticoagulation, and antiplatelet therapy is preferred in most such cases. (See  <a class="medical medical_review" href="/z/d/html/1090.html" rel="external">"Cryptogenic stroke and embolic stroke of undetermined source (ESUS)", section on 'Embolic stroke of undetermined source'</a> and  <a class="medical medical_review" href="/z/d/html/1090.html" rel="external">"Cryptogenic stroke and embolic stroke of undetermined source (ESUS)", section on 'Lack of benefit with anticoagulation'</a>.)</p><p class="headingAnchor" id="H981264722"><span class="h3">Patients with coronary artery disease</span><span class="headingEndMark"> — </span>Some patients with coronary artery disease have indications for up to 12 months of dual antiplatelet therapy (eg, recent coronary artery stent placement, acute coronary syndrome) or combined antiplatelet and anticoagulant therapy, as reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a>.)</p><p>Decisions regarding antithrombotic therapy for these patients should be individualized in consultation with neurology and cardiology, while accounting for patient preferences.</p><p class="headingAnchor" id="H2065821961"><span class="h3">Limited role of long-term dual antiplatelet therapy for stroke prevention</span><span class="headingEndMark"> — </span>For the vast majority of patients with a noncardioembolic stroke or TIA, we recommend <strong>not</strong> using <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in combination for long-term stroke prevention, given the lack of greater efficacy for dual therapy compared with either medicine alone and the substantially increased risk of bleeding complications. (See <a class="local">'Dual antiplatelet therapy'</a> below.)</p><p>Treatment with combination antiplatelet therapy has a limited role in other settings. As examples, selected patients with a recent acute myocardial infarction, other acute coronary syndrome, or arterial stent placement, including carotid stenting, are treated with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus an oral platelet P2Y<sub>12</sub> receptor blocker (ie, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, <a class="drug drug_general" data-topicid="16784" href="/z/d/drug information/16784.html" rel="external">ticagrelor</a>, or <a class="drug drug_general" data-topicid="9533" href="/z/d/drug information/9533.html" rel="external">prasugrel</a>). In these settings, most patients are not treated with dual therapy indefinitely; the exact duration is influenced by the assessment of bleeding and ischemic risks. Importantly, prasugrel is generally avoided due to an increased risk of bleeding in patients with a history of TIA or stroke, and there are essentially no long-term data for the use of ticagrelor in patients with a history of TIA or stroke.</p><p>Recommendations for combination antiplatelet therapy in these settings are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">"Overview of carotid artery stenting", section on 'Dual antiplatelet therapy'</a>.)</p><p class="headingAnchor" id="H4176824117"><span class="h3">Prevention of gastroduodenal toxicity</span><span class="headingEndMark"> — </span>For patients at increased risk of gastroduodenal toxicity from antiplatelet agents, particularly those 75 years of age or older, it is reasonable to coadminister a proton pump inhibitor [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/35.html" rel="external">"NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity"</a>.)</p><p class="headingAnchor" id="H647018904"><span class="h3">Risk of stopping antiplatelet treatment</span><span class="headingEndMark"> — </span>Stopping antiplatelet therapy in high-risk patients may itself increase the risk of stroke. One study found that 13 of 289 patients hospitalized with cerebral infarction had recently stopped antiplatelet therapy; most had been taking <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> [<a href="#rid6">6</a>]. In all 13, the antiplatelet agent had been discontinued within 6 to 10 days of stroke onset, a time course consistent with the known lifespan (approximately 10 days) of inhibited platelets. Additionally, a case-control study comparing 309 patients with stroke to 309 matched controls found that discontinuation of aspirin was associated with a significantly increased risk of TIA or ischemic stroke (odds ratio 3.4, 95% CI 1.08-10.63) [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H811608855"><span class="h3">Antiplatelet treatment failure</span><span class="headingEndMark"> — </span>Treatment failure is defined by the occurrence of a thrombotic or ischemic event (eg, stroke, TIA, or other cardiovascular occlusive event) despite adherence to antiplatelet therapy at recommended doses. Some experts prefer the term "breakthrough stroke" for a stroke that occurs despite antiplatelet therapy [<a href="#rid8">8</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Explanations</strong> – Possible explanations for antiplatelet treatment failure include antiplatelet nonresponsiveness or resistance, alternative mechanisms of stroke, poor control of modifiable comorbid stroke risk factors (eg, hypertension, diabetes mellitus, dyslipidemia, smoking, inadequate exercise), and presence of nonmodifiable risk factors (eg, increased age).</p><p></p><p class="bulletIndent1">Nonadherence to antiplatelet treatment is believed to be the most frequent cause of apparent antiplatelet resistance [<a href="#rid9">9</a>]. The issues of nonresponse and resistance to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, and the effect of enteric coating on antiplatelet activity, are reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin"</a> and  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Re-evaluation</strong> – In cases of antiplatelet treatment failure, it is important to determine the correct mechanism of stroke, including a thorough evaluation for mechanisms that are unlikely to be optimally treated with antiplatelet therapy. These include atrial fibrillation, paradoxical embolism, hemodynamic insufficiency, inflammatory or infectious vasculopathies, hypercoagulable states (eg, due to cancer), and certain genetic disorders [<a href="#rid8">8</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of laboratory testing</strong> – There is no proven role for routinely evaluating patients with antiplatelet treatment failure for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> resistance, whether by laboratory assessment or by genetic testing. (See  <a class="medical medical_review" href="/z/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin", section on 'Laboratory testing'</a> and  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure", section on 'Screening'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment considerations</strong> – The optimal antiplatelet strategy for breakthrough ischemic stroke is unknown [<a href="#rid8">8</a>]. Options include modifying the antiplatelet regimen by switching to another antiplatelet agent or continuing the existing regimen.</p><p></p><p class="bulletIndent1">When the most likely mechanism is noncardioembolic ischemic stroke, short-term dual antiplatelet therapy with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> may be indicated in the acute phase, as illustrated by the algorithm  (<a class="graphic graphic_algorithm graphicRef131701" href="/z/d/graphic/131701.html" rel="external">algorithm 2</a> and <a class="graphic graphic_algorithm graphicRef131695" href="/z/d/graphic/131695.html" rel="external">algorithm 1</a>), followed by long-term single agent antiplatelet therapy using aspirin, clopidogrel, or <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>. In general, we suggest switching to a different antiplatelet agent from the one that the patient was taking when the most recent stroke occurred. It is also important to optimize the treatment of other major cardiovascular risk factors (eg, hypertension, dyslipidemia, diabetes). These issues are discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Treatment by ischemic mechanism'</a> and  <a class="medical medical_review" href="/z/d/html/1120.html" rel="external">"Overview of secondary prevention of ischemic stroke"</a>.)</p><p></p><p class="headingAnchor" id="H216406902"><span class="h1">ANTIPLATELET AGENTS</span></p><p class="headingAnchor" id="H2"><span class="h2">Aspirin</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a>, the most commonly used antiplatelet agent, inhibits the enzyme cyclooxygenase, reducing production of thromboxane A2, a stimulator of platelet aggregation. This interferes with the formation of thrombi, thereby reducing the risk of stroke. (See  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> is a first-line antiplatelet agent for the secondary prevention of ischemic stroke. (See <a class="local">'Long-term treatment'</a> above.)</p><p class="headingAnchor" id="H2616164299"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The effectiveness of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for preventing ischemic stroke and cardiovascular events is supported by high-quality data. A 2002 meta-analysis from the Antithrombotic Trialists Collaboration (ATC) included 195 randomized controlled trials of high-risk patients found that antiplatelet treatment led to a 25 percent relative risk reduction in nonfatal stroke compared with placebo [<a href="#rid10">10</a>]. Among the subset of patients with prior cerebrovascular disease (transient ischemic attack [TIA] or stroke), antiplatelet therapy reduced the risk of recurrent stroke, myocardial infarction (MI), or vascular death by 22 percent; the absolute benefit was 36 events prevented per 1000 patients treated for 29 months. The benefit of antiplatelet therapy was independent of sex, age (greater or less than 65), diabetes, and hypertension.</p><p>Similarly, a 2009 ATC meta-analysis of 16 placebo-controlled secondary prevention trials showed that <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> reduced the risk of any serious vascular event by 19 percent and reduced the risk of ischemic stroke by 22 percent [<a href="#rid11">11</a>].</p><p>In addition to its benefit for secondary stroke prevention, treatment with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> decreases the risk of other cardiovascular events in a wide range of patients with established disease. Furthermore, there is considerable evidence that long-term aspirin use reduces the risk of death from certain cancers. (See  <a class="medical medical_review" href="/z/d/html/6893.html" rel="external">"Overview of cancer prevention", section on 'Aspirin and other antiinflammatory drugs'</a> and  <a class="medical medical_review" href="/z/d/html/110006.html" rel="external">"Aspirin for the secondary prevention of atherosclerotic cardiovascular disease"</a>.)</p><p class="headingAnchor" id="H101851411"><span class="h3">Early benefit</span><span class="headingEndMark"> — </span>In a 2016 pooled analysis of data from over 15,000 subjects in 12 trials evaluating <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for secondary prevention, the benefit of aspirin was strongest in the early weeks after TIA or ischemic stroke [<a href="#rid12">12</a>]. Aspirin reduced the relative risk of recurrent ischemic stroke within the first six weeks by 58 percent (1 versus 2.4 percent, absolute risk reduction 1.4 percent, hazard ratio [HR] 0.42, 95% CI 0.32-0.55). The benefit of aspirin in this time frame was greatest for the subgroup of patients with TIA or minor stroke (relative risk reduction of 80 percent, absolute risk reduction 0.7 percent, HR 0.19, 95% CI 0.11-0.34). Although the included secondary prevention trials treated few patients in the first days after the index stroke or TIA, similar risk reductions with aspirin were found in trials of aspirin for acute stroke and TIA, as reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack", section on 'Efficacy of aspirin'</a>.)</p><p class="headingAnchor" id="H3"><span class="h3">Dose of aspirin</span><span class="headingEndMark"> — </span>Given the apparent equivalent benefit of different doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> for ischemic stroke prevention, and the increased risk of bleeding complications with higher dose aspirin discussed below, we suggest a dose of 50 to 100 mg/day when using aspirin for the secondary prevention of noncardioembolic ischemic stroke. This recommendation is similar to the dose of 75 to 100 mg/day recommended by 2012 guidelines from the American College of Chest Physicians [<a href="#rid1">1</a>]. The 2021 American Heart Association/American Stroke Association guidelines recommend a dose of 50 to 325 mg daily [<a href="#rid2">2</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and efficacy</strong> – The dose of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in secondary stroke prevention studies ranged between 20 to 1300 mg. Most studies have found that 50 to 325 mg/day of aspirin is as effective as higher doses [<a href="#rid10">10,13-18</a>]. Furthermore, lower doses within this range appear to provide the same benefit as higher doses [<a href="#rid10">10,14,18,19</a>]. As an example, a review of 195 trials of secondary prevention by the ATC showed that doses of 75 to 150 mg/day produced the same risk reduction, compared with placebo, as doses of 150 to 325 mg/day [<a href="#rid10">10</a>]. In the ATC analysis of trials directly comparing aspirin &lt;75 mg/day with aspirin ≥75 mg/day, there was no significant difference in effectiveness between the two regimens.</p><p></p><p class="bulletIndent1">Even lower doses may be effective, as demonstrated in the Dutch TIA Trial [<a href="#rid20">20</a>]. This study found similar efficacy for stroke prevention with 30 mg compared with 283 mg of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> per day in patients who had had a TIA or minor ischemic stroke. In the European Stroke Prevention Study-2 (ESPS-2), 50 mg of aspirin daily reduced stroke risk by 18 percent compared with placebo (29 strokes prevented per 1000 treated), an effect of comparable magnitude to the other trials cited above [<a href="#rid14">14</a>]. This benefit seen with very low-dose aspirin is consistent with laboratory observations that 30 mg of aspirin per day results in complete suppression of thromboxane A2 production [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose and risk of bleeding</strong> – Lower doses of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> appear to be associated with less gastrointestinal toxicity [<a href="#rid13">13,20,22</a>]. In the United Kingdom TIA trial, for example, gastrointestinal hemorrhage occurred in 1.6 percent of patients on placebo, 2.6 percent on 300 mg aspirin, and 4.7 percent on 1200 mg aspirin [<a href="#rid13">13</a>]. A similar dose relationship was seen for milder gastrointestinal symptoms.</p><p></p><p class="bulletIndent1">In an analysis of data from 31 randomized, controlled trials, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> doses ≤200 mg/day were associated with a significantly lower rate of major bleeding events compared with higher doses [<a href="#rid23">23</a>]. However, there was no difference in major bleeding when aspirin &lt;100 mg/day was compared with 100 to 200 mg/day. When the overall rate of bleeding complications (including major, minor, and insignificant events) was considered, aspirin &lt;100 mg/day was associated with a lower risk compared with the 100 to 200 mg/day and &gt;200 mg/day groups.</p><p></p><p class="bulletIndent1">A later meta-analysis of 22 randomized trials of low-dose <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 to 325 mg/day) versus placebo for cardiovascular prophylaxis reached similar conclusions within the low-dose range [<a href="#rid24">24</a>]. Compared with placebo, aspirin increased the relative risk of any major bleeding, major gastrointestinal bleeding, and intracranial bleeding by 1.7- to 2.1-fold. However, the absolute annual increase in risk for any major bleeding episode (mostly gastrointestinal) and for intracranial bleeding was 0.13 and 0.03 percent, respectively. Furthermore, there was no evidence of an increased risk of bleeding with "high" low-dose aspirin (&gt;162 to 325 mg/day) compared with "low" low-dose aspirin (75 to 162 mg/day).</p><p></p><p class="headingAnchor" id="H3390132530"><span class="h3">Aspirin resistance</span><span class="headingEndMark"> — </span>Proposed mechanisms of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> resistance include reduced bioavailability (eg, poor compliance with therapy, reduced absorption, use of enteric-coated aspirin, inadequate dosing, drug interactions), genetic variability (eg, polymorphisms affecting cyclooxygenase-1 [COX-1], cyclooxygenase-2 [COX-2], thromboxane A2 synthase), and other factors (eg, increased isoprostane activity, accelerated platelet turnover from inflammation, infection, surgery, or stress) [<a href="#rid8">8</a>].</p><p>There is no established role for routine testing of patients for <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> resistance/nonresponsiveness. Aspirin nonresponsiveness is rare in compliant patients and is not strongly associated with clinical outcomes in published studies. (See  <a class="medical medical_review" href="/z/d/html/16946.html" rel="external">"Nonresponse and resistance to aspirin"</a>.)</p><p class="headingAnchor" id="H2911875215"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The main adverse effects of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> involve gastrointestinal toxicity (eg, ulceration, erosion) and an increased risk of gastrointestinal, intracranial, and systemic bleeding. Other adverse effects include renal complications (eg, renal insufficiency and renal failure), angioedema, bronchospasm, rash, hearing loss, tinnitus, hepatoxicity, and both allergic and pseudoallergic reactions. Salicylate toxicity may occur when higher salicylate levels are achieved. (See  <a class="medical medical_review" href="/z/d/html/329.html" rel="external">"Salicylate (aspirin) poisoning: Clinical manifestations and evaluation"</a>.)</p><p>The potential use of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> desensitization to allow for the chronic use of aspirin in individuals who are known to be sensitive or "allergic" is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/114687.html" rel="external">"Introduction of aspirin to patients with aspirin hypersensitivity requiring cardiovascular interventions"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Clopidogrel</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">Clopidogrel</a> is a thienopyridine that inhibits adenosine diphosphate (ADP)-dependent platelet aggregation. Clopidogrel is a first-line antiplatelet agent for the secondary prevention of ischemic stroke. (See <a class="local">'Long-term treatment'</a> above.)</p><p class="headingAnchor" id="H2675363851"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The CAPRIE trial randomly assigned 19,185 patients with recent stroke, MI, or symptomatic peripheral artery disease (divided roughly equally between these three enrolling diseases) to treatment with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (325 mg) or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg) [<a href="#rid25">25</a>]. The primary end point, a composite outcome of stroke, MI, or vascular death, was significantly reduced with clopidogrel treatment compared with aspirin treatment (5.3 versus 5.8 percent annually, relative risk reduction 8.7 percent, 95% CI 0.3-16.5 percent, absolute risk reduction 0.5 percent).</p><p>The benefit of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> over <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> in the CAPRIE trial varied based on enrolling disease [<a href="#rid25">25</a>]. Most of the benefit was observed in patients with peripheral artery disease, and the difference in composite outcome between clopidogrel and aspirin treatment in patients with recent stroke and MI was not significant. However, the strength of these observations is limited since they are based on subgroup analyses.</p><p class="headingAnchor" id="H2401006787"><span class="h3">Dose</span><span class="headingEndMark"> — </span>The usual dose of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> monotherapy for secondary stroke prevention is 75 mg daily.</p><p class="headingAnchor" id="H3575847430"><span class="h3">Clopidogrel resistance</span><span class="headingEndMark"> — </span>Polymorphisms in the hepatic enzymes involved in the metabolism of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (eg, CYP2C19, CYP1A2, CYP3A4) or within the platelet P2Y<sub>12</sub> receptor may affect the ability of clopidogrel to inhibit platelet aggregation. However, there are no convincing prospective data to support routine testing for clopidogrel resistance with in vitro tests of platelet function or genotyping in patients with cardiovascular disease, particularly for those with a history of stroke or TIA, and the role of platelet function testing remains unclear [<a href="#rid2">2</a>].</p><p>The issue of resistance/nonresponse to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in cardiovascular disease is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6684.html" rel="external">"Clopidogrel resistance and clopidogrel treatment failure"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>The side effect profile of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is favorable compared with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, with a slightly higher frequency of rash and diarrhea, but a slightly lower frequency of gastric upset or gastrointestinal bleeding [<a href="#rid24">24</a>]. Unlike its close relative <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> (see <a class="local">'Ticlopidine'</a> below), severe neutropenia is not seen more frequently with clopidogrel than with aspirin [<a href="#rid25">25</a>].</p><p class="headingAnchor" id="H8"><span class="h2">Aspirin plus dipyridamole</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">Dipyridamole</a> impairs platelet function by inhibiting the activity of adenosine deaminase and phosphodiesterase, which causes an accumulation of adenosine, adenine nucleotides, and cyclic adenosine monophosphate (AMP). Dipyridamole may also cause vasodilation.</p><p>The discussion below is focused on the role of the combination drug <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>, which is a first-line agent for the secondary prevention of ischemic stroke (see <a class="local">'Long-term treatment'</a> above). Immediate-release <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> is not routinely recommended for secondary prevention of ischemic stroke, given the limited evidence supporting its effectiveness and the significant pharmacokinetic differences between it and extended-release dipyridamole.</p><p class="headingAnchor" id="H1181634740"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The beneficial effects of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> for secondary stroke prevention appear to be additive such that the combination of <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> is more effective than aspirin alone [<a href="#rid14">14,26,27</a>] and similar in effectiveness to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> [<a href="#rid28">28</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>More effective than </strong><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> – In a meta-analysis of six randomized trials with 7648 patients, stroke risk was significantly reduced with aspirin plus <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> (including immediate- and extended-release formulations of dipyridamole) compared with aspirin alone (relative risk 0.77, 95% CI 0.67-0.89) [<a href="#rid26">26</a>]. Nearly 80 percent of the patients in this meta-analysis came from just two trials, ESPS-2 and ESPRIT.</p><p></p><p class="bulletIndent1">The ESPS-2 trial randomly assigned 6602 patients with a recent TIA or ischemic stroke to one of four groups: 200 mg extended-release <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> alone given twice daily; 25 mg <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone given twice daily; a combination of 25 mg aspirin plus 200 mg extended-release dipyridamole given twice daily; or placebo [<a href="#rid14">14</a>]. At 24 months of follow-up, the risk of stroke compared with placebo was reduced for both extended-release dipyridamole monotherapy (odds ratio [OR] 0.81, 95% CI 0.76-0.99) and aspirin monotherapy (OR 0.79, 95% CI 0.65-0.97). The benefit of combination <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> was greater still than the two components alone and greater than placebo (OR 0.59, 95% CI 0.48-0.73). The stroke rate was lower in the aspirin-extended-release dipyridamole group compared with the aspirin alone group (9.9 versus 12.9 percent, absolute risk reduction 3 percent) [<a href="#rid14">14</a>]. There was no difference in the risk of death or bleeding complications between the two groups, whereas both groups experienced a greater frequency of bleeding complications than the placebo group.</p><p></p><p class="bulletIndent1">In the later ESPRIT trial, 2739 patients within six months of a TIA or minor stroke of presumed arterial origin were randomly assigned to open-label treatment with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (30 to 325 mg/day) alone or aspirin plus <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> (200 mg twice daily). The median aspirin dose was 75 mg/day in both treatment groups, and the dipyridamole formulation used by most patients (83 percent) was extended release rather than immediate release [<a href="#rid27">27</a>]. Over a mean follow-up of 3.5 years, the composite primary outcome (death from all vascular causes, nonfatal stroke, nonfatal MI, or major bleeding complication) was less frequent in the aspirin plus dipyridamole group than the aspirin alone group (13 versus 16 percent, HR 0.80, 95% CI 0.66-0.98, absolute risk reduction 1.0 percent per year).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy similar to </strong><strong>clopidogrel</strong> – The PRoFESS trial showed that <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> monotherapy and <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> have similar risks and benefits for secondary stroke prevention [<a href="#rid28">28</a>]. The trial enrolled 20,332 patients with noncardioembolic ischemic stroke and randomly assigned them to treatment with either aspirin-extended-release dipyridamole (25/200 mg twice daily) or clopidogrel (75 mg once daily). At an average follow-up of 2.5 years, there was no difference between treatment with aspirin-extended-release dipyridamole or clopidogrel for the outcome of recurrent stroke (9.0 versus 8.8 percent, HR 1.01, 95% CI 0.92-1.11) or the composite outcome of stroke, MI, or vascular death (13.1 versus 13.1 percent, HR 0.99, 95% CI 0.92-1.07). Despite the nearly identical event rates for these outcomes, the trial failed to meet the prespecified noninferiority criteria for treatment with aspirin-extended-release dipyridamole. Among patients who had recurrent strokes, the rate of recurrent ischemic stroke was slightly lower in those assigned to aspirin-extended-release dipyridamole compared with clopidogrel (7.7 versus 7.9 percent), but hemorrhagic strokes were slightly increased (0.9 versus 0.5 percent). Thus, the net risk (ie, the combination of recurrent stroke plus major hemorrhage) was similar between aspirin-extended-release dipyridamole and clopidogrel (11.7 versus 11.4 percent; HR 1.03, 95% CI 0.95-1.11).</p><p></p><p class="bulletIndent1">New or worsening heart failure was slightly less frequent in patients assigned to <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> compared with those assigned to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>; the difference was significant (1.4 versus 1.8 percent, 95% CI 0.62-0.96).</p><p></p><p class="bulletIndent1">PRoFESS had a 2x2 factorial design in which the patients were also randomly assigned to <a class="drug drug_general" data-topicid="10275" href="/z/d/drug information/10275.html" rel="external">telmisartan</a> or placebo, the results of which are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3823.html" rel="external">"Antihypertensive therapy for secondary stroke prevention"</a>.)</p><p></p><p class="headingAnchor" id="H2068916663"><span class="h3">Dose</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">Aspirin-extended-release dipyridamole</a>, containing <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (25 mg) plus extended-release <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> (200 mg), is given two times per day. Dipyridamole is also available as an immediate-release form, usually given as 50 to 100 mg three times per day, but this is seldom used alone for secondary stroke prevention.</p><p>The specific <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> preparation may be important. In a meta-analysis cited above, the combination of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and immediate-release dipyridamole was nonsignificantly better than aspirin alone for secondary prevention of stroke (relative risk 0.83, 95% CI 0.59-1.15) [<a href="#rid26">26</a>]. By contrast, extended release dipyridamole was used in all or the vast majority of patients in the much larger ESPS-2 and ESPRIT trials [<a href="#rid14">14,27</a>], and <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> led to a greater reduction in stroke risk compared with aspirin alone [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H9"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>Headache is the most common adverse effect of <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a>, and one that most often leads to discontinuation of treatment. Other adverse reactions include abdominal pain, nausea, diarrhea, and vomiting.</p><p>Headache was the most frequent adverse event associated with <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> in two large clinical trials, ESPS-2 and ESPRIT [<a href="#rid14">14,27</a>]. In the PRoFESS trial, discontinuation due to headache was more frequent with aspirin-extended-release dipyridamole compared with <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (5.9 versus 0.9 percent) [<a href="#rid28">28</a>]. In a study of subjects aged 55 or older treated with the combination of aspirin-extended-release dipyridamole, headache developed in 39.7 percent after a single dose, and women were significantly more likely to develop headache than men (49.6 and 28.6 percent, respectively) [<a href="#rid29">29</a>]. The headaches associated with aspirin-extended-release dipyridamole treatment were mostly self-limited, and treatment of headache with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a> was not significantly better than with placebo, as measured by response at two hours (75.5 and 69.4 percent). The overall incidence of headache declined markedly over seven days to less than 20 percent. Gastric upset and/or diarrhea requiring drug cessation was also more common with <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> compared with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or placebo in ESPS-2.</p><p>Notably, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> use was associated with significantly greater overall bleeding and gastrointestinal bleeding compared with <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> or placebo in ESPS-2 and a subsequent meta-analysis [<a href="#rid14">14,30</a>]. In fact, in ESPS-2, the frequency of bleeding complications with dipyridamole was comparable to placebo.</p><p>Concern that <a class="drug drug_general" data-topicid="9377" href="/z/d/drug information/9377.html" rel="external">dipyridamole</a> use might lead to increased rates of myocardial ischemia has been largely laid to rest by data from two large clinical trials (ESPS-2 and ESPRIT) and a meta-analysis [<a href="#rid14">14,27,30,31</a>]. This concern was related to the potential for dipyridamole to cause vasodilation of coronary vessels [<a href="#rid32">32</a>], and it first arose with the use of intravenous dipyridamole in cardiac stress testing [<a href="#rid33">33</a>]. However, accumulating data suggest that extended-release dipyridamole use for stroke prevention is <strong>not</strong> associated with an increased risk of myocardial ischemia or infarction. An analysis of data from ESPS-2 found that use of extended-release dipyridamole was not associated with increased cardiac ischemia or mortality in patients with a history of coronary artery disease [<a href="#rid31">31</a>], and a meta-analysis found that oral dipyridamole did not alter the rate of MI in patients with previous stroke or TIA, either when compared with control, or when administered in combination with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and compared with aspirin alone [<a href="#rid30">30</a>]. In ESPRIT, the use of combination therapy with aspirin and dipyridamole, mainly extended-release dipyridamole, was associated with a nonsignificant decrease in the outcome of first cardiac event, and a significant decrease in the primary composite outcome that included death from all vascular causes and nonfatal MI [<a href="#rid27">27</a>].</p><p class="headingAnchor" id="H105978174"><span class="h2">Cilostazol</span><span class="headingEndMark"> — </span>The antiplatelet agent <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> is a phosphodiesterase 3 inhibitor that increases cyclic AMP and leads to reversible inhibition of platelet aggregation and arterial vasodilation.</p><p class="headingAnchor" id="H3188084195"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>Several randomized controlled trials and meta-analyses have found that <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> is effective for preventing cerebral infarction [<a href="#rid34">34-36</a>].</p><p>In the CSPS trial of over 1000 patients from Japan, <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> (100 mg twice daily) compared with placebo reduced the risk of stroke (relative risk reduction [RRR] 42 percent, 95% CI 9.2-62.5 percent) [<a href="#rid34">34</a>]. The CSPS II trial randomly assigned 2757 patients in Japan with a recent noncardioembolic cerebral infarction to cilostazol (100 mg twice daily) or <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (81 mg daily) [<a href="#rid35">35</a>]. At a mean follow-up of 29 months, the yearly rates of recurrent stroke (infarction or hemorrhage) for cilostazol and aspirin were 2.7 and 3.7 percent (HR 0.74, 95% CI 0.56-0.98), confirming that cilostazol is noninferior to aspirin for stroke prevention. Annual rates of intracranial hemorrhage or other hemorrhage requiring hospitalization were lower with cilostazol than with aspirin (0.8 versus 1.8 percent, HR 0.46, 95% CI 0.30-0.71).</p><p>In the CASISP trial from China of 720 patients with recent ischemic stroke, the composite endpoint (any stroke, ischemic or hemorrhagic) at 12 to 18 months of follow-up was lower in the <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> group compared with the <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> group (3.3 versus 5.6 percent), but this result was not statistically significant (HR 0.62, 95% CI 0.30-1.26) [<a href="#rid37">37</a>].</p><p>These data support the safety and efficacy of <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> for secondary stroke prevention in East Asian populations. However, there are as yet no high-quality data regarding the use of cilostazol for secondary stroke prevention in non-East Asian ethnic groups. Also, the twice daily dosing, lower tolerability, and higher cost of cilostazol compared with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> may limit its more widespread use for stroke prevention.</p><p class="headingAnchor" id="H467558519"><span class="h3">Dosing</span><span class="headingEndMark"> — </span>The dose of <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> is 100 mg twice daily.</p><p class="headingAnchor" id="H1130287716"><span class="h3">Adverse effects</span><span class="headingEndMark"> — </span>In the CSPS II trial of <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> versus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, headache, diarrhea, palpitation, dizziness, and tachycardia were more frequent with cilostazol, and more patients discontinued cilostazol than aspirin (20 versus 12 percent) [<a href="#rid35">35</a>]. Other potential adverse reactions include diarrhea, infection, and rhinitis.</p><p class="headingAnchor" id="H844372062"><span class="h2">Others</span></p><p class="headingAnchor" id="H1054729434"><span class="h3">Ticlopidine</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">Ticlopidine</a> is a thienopyridine with a chemical structure and mechanism of action similar to <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>. Despite the evidence of benefit in randomized trials, ticlopidine is <strong>not</strong> considered a first-line antiplatelet agent for stroke prevention because of the risk of severe neutropenia and relatively high cost.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy </strong>– The CATS trial enrolled over 1000 patients between one week and four months after ischemic stroke [<a href="#rid38">38</a>]. At a mean of 24 months, the primary composite end point of stroke, MI, and vascular death was lower with <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> compared with placebo (10.8 versus 15.3 percent, RRR 30 percent). The benefit was smaller by intention-to-treat analysis (RRR 23 percent). The TASS trial compared ticlopidine (500 mg/d) with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (1300 mg/d) in 3069 patients with a recent TIA or mild stroke [<a href="#rid39">39</a>]. At three-year follow-up, ticlopidine reduced the primary end point (nonfatal stroke or death) compared with aspirin (17 versus 19 percent). Ticlopidine also reduced the rate of fatal and nonfatal stroke compared with aspirin (10 versus 13 percent, respectively, RRR 21 percent, 95% CI 4-38).</p><p></p><p class="bulletIndent1">The AAASPS trial compared <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> (500 mg/day) with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (650 mg/day) in 1809 Black patients with noncardioembolic ischemic stroke [<a href="#rid40">40</a>]. At two-year follow-up, there was no significant difference in the primary end point (stroke, MI, vascular death) between ticlopidine and aspirin.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose</strong> – The dose of <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> is 250 mg twice daily. The drug is no longer available in the United States.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – The most serious complication of <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a> therapy is severe neutropenia, which occurs in approximately 1 percent of patients. Thus, patients must have a complete blood count with differential prior to treatment initiation and then weekly for the first three months of therapy; more frequent monitoring is recommended for patients whose absolute neutrophil counts are consistently declining or are 30 percent less than baseline. Other common side effects, which occur more frequently with ticlopidine than <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, are rash and diarrhea.</p><p></p><p class="headingAnchor" id="H16"><span class="h3">Triflusal</span><span class="headingEndMark"> — </span>Triflusal is an antiplatelet agent that is structurally related to <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>. It is available as a licensed pharmaceutical in some European and Latin American countries but is considered investigational in the United States. In a randomized trial with 2113 patients, the effectiveness of triflusal (600 mg/day) was similar to aspirin (325 mg/day) at preventing vascular events after stroke, but it did have a lower rate of hemorrhagic complications [<a href="#rid41">41</a>]. Similar findings were noted in a smaller randomized trial and a meta-analysis of four trials [<a href="#rid42">42,43</a>]. It is not clear whether triflusal would have had a lower rate of hemorrhagic complications than lower-dose aspirin [<a href="#rid44">44</a>].</p><p class="headingAnchor" id="H2608380329"><span class="h2">Dual antiplatelet therapy</span><span class="headingEndMark"> — </span>The short-term use of dual antiplatelet therapy (DAPT) with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> is beneficial compared with aspirin alone in some patients with acute ischemic stroke syndromes  (<a class="graphic graphic_algorithm graphicRef131695" href="/z/d/graphic/131695.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131701" href="/z/d/graphic/131701.html" rel="external">algorithm 2</a>), as reviewed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p>However, evidence from randomized trials suggests that long-term DAPT has no such benefit for stroke risk reduction, but rather appears to be harmful due to an increased risk of bleeding.</p><p class="headingAnchor" id="H2160809672"><span class="h3">Aspirin plus clopidogrel</span><span class="headingEndMark"> — </span>For the vast majority of patients with ischemic stroke, the long-term use of DAPT with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> does <strong>not</strong> offer greater benefit for stroke prevention than either agent alone but does substantially increase the risk of bleeding complications [<a href="#rid45">45-49</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>The MATCH trial enrolled 7599 patients with stroke or TIA who also had some additional "high-risk" feature, defined as prior MI, prior stroke (in addition to the index event), diabetes, angina, or symptomatic peripheral artery disease [<a href="#rid45">45</a>]. Patients were randomly assigned to the combination of <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> (75 mg daily) plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (75 mg daily) or clopidogrel (75 mg daily) alone. Follow-up was 18 months. Compared with clopidogrel alone, aspirin plus clopidogrel treatment did <strong>not</strong> reduce the risk of major vascular events (relative risk reduction 6.4 percent, 95% CI -4.6 to 16.3 percent) but did result in more life-threatening bleeding complications, mainly intracranial and gastrointestinal. Over the 18-month trial period, there was an absolute excess of 1.3 percent for life-threatening hemorrhage (95% CI 0.6-1.9) and an additional 1.3 percent for major hemorrhage in patients assigned combination therapy. Overall, treatment with aspirin and clopidogrel compared with clopidogrel alone might prevent 10 ischemic events per 1000 at the cost of 13 life-threatening hemorrhages per 1000 treated.</p><p></p><p class="bulletIndent1">There are several limitations of MATCH. For instance, 54 percent of MATCH subjects qualified for trial entry because of a lacunar stroke, a stroke subtype that has the lowest recurrence risk [<a href="#rid50">50</a>]. Furthermore, data regarding interaction between treatment and stroke mechanism were not reported, raising the question of whether combination therapy might still play a role in particular stroke subtypes.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The CHARISMA trial evaluated <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> versus aspirin alone in 15,603 patients with either documented cardiovascular disease (coronary, ischemic cerebrovascular, or peripheral arterial) or, in 21 percent of patients, multiple atherothrombotic risk factors (eg, diabetes, hypertension, primary hypercholesterolemia, current smoking, asymptomatic carotid stenosis ≥70 percent) [<a href="#rid46">46</a>]. Patients were randomly assigned to low-dose aspirin (75 to 162 mg/day) plus either clopidogrel (75 mg/day) or placebo. At a median follow-up of 28 months, combined aspirin plus clopidogrel treatment did not reduce the risk of the composite end point (MI, stroke of any cause, or death from cardiovascular causes) compared with aspirin alone (6.8 versus 7.3 percent, relative risk 0.93, 95% CI 0.83-1.05), but did increase in moderate bleeding (2.1 versus 1.3 percent) and severe bleeding (1.7 versus 1.3 percent), although the latter did not reach statistical significance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SPS3 trial evaluated over 3000 patients with subcortical (ie, lacunar) stroke confirmed by magnetic resonance imaging (MRI) [<a href="#rid51">51</a>]. The arm testing the combination of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> plus <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> versus aspirin alone was terminated before completion because of a higher frequency of bleeding events (mostly systemic) and a higher mortality rate in patients assigned to DAPT compared with those assigned to aspirin only. In the final analysis, subjects treated with aspirin plus clopidogrel compared with aspirin alone had a significantly increased annual rate of both major hemorrhage (2.1 versus 1.1 percent, HR 1.97, 95% CI 1.41-2.71) and all-cause mortality (2.1 versus 1.4 percent, HR 1.52, 95% CI 1.14-2.04) [<a href="#rid49">49</a>]. Furthermore, treatment with aspirin and clopidogrel compared with aspirin alone in did not reduce the risk of recurrent stroke [<a href="#rid49">49</a>].</p><p></p><p class="headingAnchor" id="H2924445995"><span class="h3">Cilostazol plus aspirin or clopidogrel</span><span class="headingEndMark"> — </span>The potential utility of DAPT using <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> was explored in the open-label CSPS.com trial in Japan, which enrolled 1884 adult patients with noncardioembolic ischemic stroke who had ≥50 percent stenosis of a major intracranial or extracranial artery, or two or more vascular risk factors [<a href="#rid52">52</a>]. The patients were assigned in a 1:1 ratio to antiplatelet monotherapy using either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, or to DAPT using cilostazol combined with either aspirin or clopidogrel [<a href="#rid52">52</a>]. During a median follow-up of 1.4 years, the rate of recurrent ischemic stroke was lower for the DAPT group compared with the monotherapy group (3 versus 7 percent, HR 0.49, 95% CI 0.31-0.76). The rates of serious adverse events and bleeding events were similar between the groups. Limitations to this trial include early stopping before reaching the planned 4000 enrollment due to slow recruitment, resulting in a lower number of event rates, the varying combinations of antiplatelet medications and dosages of aspirin, and the unblinded treatment.</p><p class="headingAnchor" id="H2288922957"><span class="h2">Combination antiplatelet and anticoagulant therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a> combined with low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (2.5 orally twice a day) is another reasonable treatment option for some patients with non-lacunar, non-cardioembolic ischemic stroke and evidence of systemic atherosclerosis.</p><p>This approach is based primarily on the results of the COMPASS trial, which randomly assigned over 27,000 patients with stable coronary artery disease or peripheral arterial disease to one of three treatment arms: one, <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily plus <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 100 mg daily; two, rivaroxaban 5 mg twice daily; or three, aspirin 100 mg daily [<a href="#rid53">53</a>]. Patients with a history of lacunar stroke or with cardioembolic stroke requiring anticoagulation were excluded from enrollment. The mean follow-up was 23 months. Compared with those assigned to aspirin alone, patients assigned to rivaroxaban plus aspirin had a decrease in the annualized composite outcome of cardiovascular mortality, stroke, or myocardial infarction (4.1 versus 5.4 percent, absolute risk reduction [ARR] 1.3 percent, HR 0.76, 95% CI 0.66 to 0.86) and a decrease in ischemic stroke (0.7 versus 1.4 percent, ARR 0.7 percent, HR 0.51, 95% CI 0.38-0.68). Similarly, in the subgroup of 1032 patients with prior stroke, aspirin and rivaroxaban decreased the composite rate of cardiovascular death, stroke, or myocardial infarction (3.7 percent, versus 6.5 percent with aspirin alone, ARR 2.8 percent, HR 0.57, 95% CI 0.34-0.96) [<a href="#rid54">54</a>]; thus, the ARR for patients with prior stroke was more than double that observed for the overall trial cohort.</p><p>As expected, those assigned to combination therapy in COMPASS had an increase in major bleeding events (3.1 versus 1.9 percent, absolute risk increase 1.2 percent, HR 1.70, 95% CI 1.40-2.05), with the gastrointestinal tract being the most common site of major bleeding [<a href="#rid53">53</a>]. However, there was no difference between the two groups in fatal bleeding (0.2 versus 0.1 percent) or intracranial bleeding (0.2 percent in both arms).</p><p>Similar findings for risk reduction of ischemic stroke were reported in the COMMANDER-HF trial, which randomly assigned over 5000 patients with chronic heart failure, left ventricular ejection fraction ≤40 percent, coronary artery disease, elevated plasma natriuretic peptide level, and no atrial fibrillation to receive <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> 2.5 mg twice daily or placebo [<a href="#rid55">55</a>]. At baseline, approximately 93 percent of the patients were on <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> (alone or in combination with a thienopyridine), and approximately 35 percent were taking DAPT. During a median follow-up of 21 months, there was no significant difference in all-cause mortality between the rivaroxaban and placebo groups, but the risk of stroke was reduced in the group assigned to rivaroxaban (2 versus 3 percent, ARR 1 percent, HR 0.66, 95% CI 0.47-0.95). The risk of major bleeding was higher in the rivaroxaban group (3.3 versus 2.0 percent), but there was no significant difference between groups for fatal bleeding (0.4 percent in both groups) or for bleeding into a critical space (0.5 versus 0.8 percent).</p><p class="headingAnchor" id="H1765719891"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/105370.html" rel="external">"Society guideline links: Stroke in adults"</a>.)</p><p class="headingAnchor" id="H28958176"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15328.html" rel="external">"Patient education: Stroke (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16238.html" rel="external">"Patient education: Medicines after an ischemic stroke (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/726.html" rel="external">"Patient education: Stroke symptoms and diagnosis (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/727.html" rel="external">"Patient education: Transient ischemic attack (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/723.html" rel="external">"Patient education: Ischemic stroke treatment (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H19"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute antiplatelet therapy</strong> – The use of antiplatelet therapy in the acute period of ischemic stroke and transient ischemic attack (TIA), including the short-term use of dual antiplatelet therapy (DAPT), is discussed in detail elsewhere  (<a class="graphic graphic_algorithm graphicRef131695" href="/z/d/graphic/131695.html" rel="external">algorithm 1</a> and <a class="graphic graphic_algorithm graphicRef131701" href="/z/d/graphic/131701.html" rel="external">algorithm 2</a>). (See  <a class="medical medical_review" href="/z/d/html/1082.html" rel="external">"Early antithrombotic treatment of acute ischemic stroke and transient ischemic attack"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Options for long-term antiplatelet therapy</strong> – <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">Aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, and the combination of <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> are all acceptable options for preventing recurrent noncardioembolic ischemic stroke. <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> is a reasonable option for patients of East Asian ethnicity, and for all patients if the other agents are not available or tolerated. (See <a class="local">'Aspirin'</a> above and <a class="local">'Clopidogrel'</a> above and <a class="local">'Aspirin plus dipyridamole'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Our recommendations</strong> – For secondary prevention of stroke in patients with a history of noncardioembolic stroke or TIA of atherothrombotic, lacunar (small vessel occlusive type), or cryptogenic type, we recommend treatment with an antiplatelet agent using either <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a>, <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a>, or <a class="drug drug_general" data-topicid="8664" href="/z/d/drug information/8664.html" rel="external">aspirin-extended-release dipyridamole</a> (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). We suggest antiplatelet therapy using either clopidogrel (75 mg daily) as monotherapy or the combination of aspirin-extended-release dipyridamole (25 mg/200 mg twice a day), rather than aspirin alone (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). The choice between clopidogrel and aspirin-extended-release dipyridamole is dependent mainly on patient tolerance and contraindications. Aspirin is appropriate for patients who cannot afford or tolerate clopidogrel or aspirin-extended-release dipyridamole. (See <a class="local">'Aspirin'</a> above and <a class="local">'Clopidogrel'</a> above and <a class="local">'Aspirin plus dipyridamole'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Aspirin</strong><strong> dose</strong> – Although the optimal dose of <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> is uncertain, there is no compelling evidence that any specific dose is more effective than another, and fewer gastrointestinal side effects and bleeding occur with lower doses (≤325 mg a day). We recommend a dose of 50 to 100 mg daily when using aspirin for the secondary prevention of ischemic stroke (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). (See <a class="local">'Dose of aspirin'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Limited role for long-term dual antiplatelet therapy</strong> – For most patients with a noncardioembolic stroke or TIA, we recommend <strong>not</strong> using <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> in combination for long-term stroke prevention, given the lack of greater efficacy compared with clopidogrel alone and the substantially increased risk of bleeding complications (<a class="grade" href="https:///uptodate/show/grade_1" rel="external">Grade 1A</a>). (See <a class="local">'Aspirin plus clopidogrel'</a> above.)</p><p></p><p class="bulletIndent1">Possible exceptions include patients with concurrent indications for dual antiplatelet therapy (eg, selected patients with a recent acute myocardial infarction, other acute coronary syndrome, or arterial stent placement including carotid stenting); these are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/1576.html" rel="external">"Antithrombotic therapy for elective percutaneous coronary intervention: General use"</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients"</a> and  <a class="medical medical_review" href="/z/d/html/1104.html" rel="external">"Overview of carotid artery stenting"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Role of combined antiplatelet and anticoagulant therapy</strong> – For high-risk patients with noncardioembolic, nonlacunar stroke and evidence of peripheral, coronary, or cerebrovascular atherosclerosis, <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> combined with low-dose <a class="drug drug_general" data-topicid="9498" href="/z/d/drug information/9498.html" rel="external">rivaroxaban</a> (2.5 orally twice a day) is a reasonable treatment option. (See <a class="local">'Combination antiplatelet and anticoagulant therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation</strong> – Prevention of recurrent cardioembolic stroke in patients with atrial fibrillation is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lansberg MG, O'Donnell MJ, Khatri P, et al. Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e601S.</a></li><li><a class="nounderline abstract_t">Kleindorfer DO, Towfighi A, Chaturvedi S, et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. Stroke 2021; 52:e364.</a></li><li><a class="nounderline abstract_t">Greving JP, Diener HC, Reitsma JB, et al. Antiplatelet Therapy After Noncardioembolic Stroke. Stroke 2019; 50:1812.</a></li><li><a class="nounderline abstract_t">Guzik A, Bushnell C. Stroke Epidemiology and Risk Factor Management. Continuum (Minneap Minn) 2017; 23:15.</a></li><li><a class="nounderline abstract_t">Li L, Geraghty OC, Mehta Z, et al. Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study. Lancet 2017; 390:490.</a></li><li><a class="nounderline abstract_t">Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62:1187.</a></li><li><a class="nounderline abstract_t">Maulaz AB, Bezerra DC, Michel P, Bogousslavsky J. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62:1217.</a></li><li><a class="nounderline abstract_t">John S, Katzan I. Recurrent Stroke while on Antiplatelet Therapy. Neurol Clin 2015; 33:475.</a></li><li><a class="nounderline abstract_t">Schwartz KA, Schwartz DE, Barber K, et al. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008; 6:46.</a></li><li><a class="nounderline abstract_t">Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71.</a></li><li><a class="nounderline abstract_t">Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373:1849.</a></li><li><a class="nounderline abstract_t">Rothwell PM, Algra A, Chen Z, et al. Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet 2016; 388:365.</a></li><li><a class="nounderline abstract_t">Farrell B, Godwin J, Richards S, Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54:1044.</a></li><li><a class="nounderline abstract_t">Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996; 143:1.</a></li><li><a class="nounderline abstract_t">United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br Med J (Clin Res Ed) 1988; 296:316.</a></li><li><a class="nounderline abstract_t">Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br Med J (Clin Res Ed) 1988; 296:320.</a></li><li><a class="nounderline abstract_t">The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet 1987; 2:1351.</a></li><li><a class="nounderline abstract_t">Johnson ES, Lanes SF, Wentworth CE 3rd, et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch Intern Med 1999; 159:1248.</a></li><li><a class="nounderline abstract_t">Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med 2021; 384:1981.</a></li><li><a class="nounderline abstract_t">Dutch TIA Trial Study Group, van Gijn J, Algra A, et al. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 1991; 325:1261.</a></li><li><a class="nounderline abstract_t">Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373.</a></li><li><a class="nounderline abstract_t">Hirsh J, Dalen JE, Fuster V, et al. Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. Chest 1995; 108:247S.</a></li><li><a class="nounderline abstract_t">Serebruany VL, Steinhubl SR, Berger PB, et al. Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005; 95:1218.</a></li><li><a class="nounderline abstract_t">McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006; 119:624.</a></li><li><a class="nounderline abstract_t">CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996; 348:1329.</a></li><li><a class="nounderline abstract_t">Verro P, Gorelick PB, Nguyen D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 2008; 39:1358.</a></li><li><a class="nounderline abstract_t">ESPRIT Study Group, Halkes PH, van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006; 367:1665.</a></li><li><a class="nounderline abstract_t">Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008; 359:1238.</a></li><li><a class="nounderline abstract_t">Lipton RB, Bigal ME, Kolodner KB, et al. Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination. Neurology 2004; 63:1099.</a></li><li><a class="nounderline abstract_t">Leonardi-Bee J, Bath PM, Bousser MG, et al. Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke 2005; 36:162.</a></li><li><a class="nounderline abstract_t">Diener HC, Darius H, Bertrand-Hardy JM, et al. Cardiac safety in the European Stroke Prevention Study 2 (ESPS2). Int J Clin Pract 2001; 55:162.</a></li><li><a class="nounderline abstract_t">Tran H, Anand SS. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease. JAMA 2004; 292:1867.</a></li><li><a class="nounderline abstract_t">Pfisterer M. Intravenous dipyridamole for stress thallium-201 perfusion scintigraphy. Cardiovasc Imag 1992; 4:31.</a></li><li><a class="nounderline abstract_t">Matsumoto M. Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study. Atheroscler Suppl 2005; 6:33.</a></li><li><a class="nounderline abstract_t">Shinohara Y, Katayama Y, Uchiyama S, et al. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010; 9:959.</a></li><li><a class="nounderline abstract_t">Kim SM, Jung JM, Kim BJ, et al. Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis. Stroke 2019; 50:3503.</a></li><li><a class="nounderline abstract_t">Huang Y, Cheng Y, Wu J, et al. Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study. Lancet Neurol 2008; 7:494.</a></li><li><a class="nounderline abstract_t">Gent M, Blakely JA, Easton JD, et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1989; 1:1215.</a></li><li><a class="nounderline abstract_t">Hass WK, Easton JD, Adams HP Jr, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N Engl J Med 1989; 321:501.</a></li><li><a class="nounderline abstract_t">Gorelick PB, Richardson D, Kelly M, et al. Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial. JAMA 2003; 289:2947.</a></li><li><a class="nounderline abstract_t">Matías-Guiu J, Ferro JM, Alvarez-Sabín J, et al. Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial. Stroke 2003; 34:840.</a></li><li><a class="nounderline abstract_t">Culebras A, Rotta-Escalante R, Vila J, et al. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. Neurology 2004; 62:1073.</a></li><li><a class="nounderline abstract_t">Costa J, Ferro JM, Matias-Guiu J, et al. Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev 2005; :CD004296.</a></li><li><a class="nounderline abstract_t">Anderson DC, Goldstein LB. Aspirin: it's hard to beat. Neurology 2004; 62:1036.</a></li><li><a class="nounderline abstract_t">Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:331.</a></li><li><a class="nounderline abstract_t">Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706.</a></li><li><a class="nounderline abstract_t">Usman MH, Notaro LA, Nagarakanti R, et al. Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble? Am J Cardiol 2009; 103:1107.</a></li><li><a class="nounderline abstract_t">Lee M, Saver JL, Hong KS, et al. Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013; 159:463.</a></li><li><a class="nounderline abstract_t">SPS3 Investigators, Benavente OR, Hart RG, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012; 367:817.</a></li><li><a class="nounderline abstract_t">Amarenco P, Donnan GA. Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin? Stroke 2004; 35:2606.</a></li><li class="breakAll">Clinical advisory: Secondary Prevention of Small Subcortical Strokes trial: NINDS stops treatment with combination antiplatelet therapy (clopidogrel plus aspirin) due to higher risk of major hemorrhage and death. www.nlm.nih.gov/databases/alerts/2011_ninds_stroke.html (Accessed on November 28, 2011).</li><li><a class="nounderline abstract_t">Toyoda K, Uchiyama S, Yamaguchi T, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial. Lancet Neurol 2019; 18:539.</a></li><li><a class="nounderline abstract_t">Eikelboom JW, Connolly SJ, Bosch J, et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N Engl J Med 2017; 377:1319.</a></li><li><a class="nounderline abstract_t">Sharma M, Hart RG, Connolly SJ, et al. Stroke Outcomes in the COMPASS Trial. Circulation 2019; 139:1134.</a></li><li><a class="nounderline abstract_t">Zannad F, Anker SD, Byra WM, et al. Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease. N Engl J Med 2018; 379:1332.</a></li></ol></div><div id="topicVersionRevision">Topic 1086 Version 56.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315273" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Antithrombotic and thrombolytic therapy for ischemic stroke: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34024117" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31177983" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Antiplatelet Therapy After Noncardioembolic Stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28157742" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Stroke Epidemiology and Risk Factor Management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28622955" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079022" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Antiplatelet drug discontinuation is a risk factor for ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16087761" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25907917" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Recurrent Stroke while on Antiplatelet Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18759978" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11786451" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19482214" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27209146" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1783914" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8981292" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2894232" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3125883" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2890951" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10371234" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A metaregression analysis of the dose-response effect of aspirin on stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33999548" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1922220" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16319386" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Low-dose aspirin for the prevention of atherothrombosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7555180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15877994" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16887404" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918275" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18323511" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16714187" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18753638" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15452309" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acetaminophen in the treatment of headaches associated with dipyridamole-aspirin combination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15569877" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11351768" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Cardiac safety in the European Stroke Prevention Study 2 (ESPS2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15494585" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Intravenous dipyridamole for stress thallium-201 perfusion scintigraphy</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16275125" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Cilostazol in secondary prevention of stroke: impact of the Cilostazol Stroke Prevention Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20833591" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31607242" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Cilostazol Mono and Combination Treatments in Ischemic Stroke: An Updated Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18456558" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2566778" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2761587" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12799402" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12649515" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Comparison of triflusal and aspirin for prevention of vascular events in patients after cerebral infarction: the TACIP Study: a randomized, double-blind, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15079004" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16034926" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Triflusal for preventing serious vascular events in people at high risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15078996" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Aspirin: it's hard to beat.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15276392" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16531616" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19361598" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Combination antiplatelet therapy for secondary stroke prevention: enhanced efficacy or double trouble?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24081287" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931315" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effects of clopidogrel added to aspirin in patients with recent lacunar stroke.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472090" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15472090" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Should the MATCH results be extrapolated to all stroke patients and affect ongoing trials evaluating clopidogrel plus aspirin?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31122494" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844192" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30667279" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Stroke Outcomes in the COMPASS Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146935" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
